Clinical Trial Update: Cubicin(R) for Complicated Post-surgical Wound Infections [Phase 4]

View source ↗

Summary

The Phase 4 trial of Cubicin for complicated post-surgical wound infections was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Surgical Site Infection

Drugs mentioned

• Cubicin (daptomycin)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Wound Infections | Phase 4 | Status: TERMINATED